– MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis –
– The trial did not meet its primary endpoint; results support Ocrevus IV 600 mg as the optimal dose to slow disability progression –
– High dose was well tolerated with an overall comparable safety profile to Ocrevus IV 600 mg and no new safety signals observed –
– These data further support the efficacy and safety profile of Ocrevus IV 600 mg dose for RMS –
– Ocrevus set a new standard of care in multiple sclerosis and is the most prescribed disease modifying therapy in the United States with more than 400,000 people treated globally –
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose in people with relapsing multiple sclerosis (RMS) did not meet its primary endpoint in showing additional benefit in slowing disability progression, as measured by a composite disability endpoint over a period of at least 120 weeks of treatment. The rates of disability progression were low and consistent with rates observed in the previous pivotal studies of Ocrevus IV 600 mg. In addition, in several predefined analyses on disease activity, Ocrevus IV 600 mg showed clinically meaningful results with the lowest annualized relapse rate (ARR) observed during the double-blind period of a Phase III study in RMS. The MUSETTE data further support the efficacy and safety profile of the currently approved Ocrevus IV 600 mg dose for RMS.
“Ocrevus is the first and only B-cell therapy approved for RMS and PPMS and after more than ten years of treatment, the majority of people with RMS remain free from disease progression,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression. Moreover, in several predefined analyses on disease activity, Ocrevus showed clinically meaningful results on relapses with a relapse occurring approximately once every 16 years, a first for an anti-CD20 RMS medicine.”
Since its launch, Ocrevus has set a new standard of care in MS and is the most prescribed disease modifying therapy in the United States with more than 400,000 people treated globally. With the recent launch of Ocrevus Zunovo™, we aim to improve the treatment experience for people living with multiple sclerosis and expand Ocrevus usage in centers without IV infrastructure or those with IV capacity limitations. In addition, we are developing a novel high concentration formulation for even more convenient on-body device delivery to bring Ocrevus treatment closer to home.
CLICK HERE TO CONTINUE READING
